open access

Vol 12, No 2 (2017)
Cardiology Investigation
Published online: 2017-04-20
Get Citation

Cardiac assessment of patients with liver failure in the evaluation program before liver transplantation

Michalina Galas, Renata Główczyńska, Gabriela Parol
DOI: 10.5603/FC.2017.0036
·
Folia Cardiologica 2017;12(2):220-227.

open access

Vol 12, No 2 (2017)
Cardiology Investigation
Published online: 2017-04-20

Abstract

Liver transplantation is assumed to be a very invasive, extensive and long-lasting surgery, classified, according to the European Society of Cardiology, as a surgery of the highest cardiovascular risk with 5 percent risk of cardiovascular death and myocardial infarction within 30 days after surgery. Liver failure is associated with cardiovascular complications of cirrhosis including cardiac dysfunction and abnormalities in the central, peripheral and splanchnic circulation and some haemodynamic changes. Portal hypertension is accompanied with the hyperkinetic circulation, which results in complications such as cirrhotic cardiomyopathy. Hepatopulmonary syndrome is also a result of liver disease. The aim of the cardiac assessment in this group of patients is an early identification of the specific cardiovascular pathologies. This constitutes an essential element of the qualification process of candidates for transplantation and important information about the increased risk of complications during the perioperative period for an interdisciplinary team.

Abstract

Liver transplantation is assumed to be a very invasive, extensive and long-lasting surgery, classified, according to the European Society of Cardiology, as a surgery of the highest cardiovascular risk with 5 percent risk of cardiovascular death and myocardial infarction within 30 days after surgery. Liver failure is associated with cardiovascular complications of cirrhosis including cardiac dysfunction and abnormalities in the central, peripheral and splanchnic circulation and some haemodynamic changes. Portal hypertension is accompanied with the hyperkinetic circulation, which results in complications such as cirrhotic cardiomyopathy. Hepatopulmonary syndrome is also a result of liver disease. The aim of the cardiac assessment in this group of patients is an early identification of the specific cardiovascular pathologies. This constitutes an essential element of the qualification process of candidates for transplantation and important information about the increased risk of complications during the perioperative period for an interdisciplinary team.

Get Citation

Keywords

cardiac assessment, cirrhotic cardiomyopathy, liver failure

About this article
Title

Cardiac assessment of patients with liver failure in the evaluation program before liver transplantation

Journal

Folia Cardiologica

Issue

Vol 12, No 2 (2017)

Pages

220-227

Published online

2017-04-20

DOI

10.5603/FC.2017.0036

Bibliographic record

Folia Cardiologica 2017;12(2):220-227.

Keywords

cardiac assessment
cirrhotic cardiomyopathy
liver failure

Authors

Michalina Galas
Renata Główczyńska
Gabriela Parol

References (23)
  1. Poldermans D, Bax JJ, Boersma E, et al. Grupa Robocza Europejskiego Towarzystwa Kardiologicznego (ESC) do spraw oceny ryzyka sercowego oraz okołooperacyjnego postępowania kardiologicznego u pacjentów poddawanych zabiegom niekardiologicznym, we współpracy z Europejskim Towarzystwem Anestezjologicznym (ESA). Wytyczne Europejskiego Towarzystwa Kardiologicznego dotyczące przedoperacyjnej oceny ryzyka sercowego oraz okołooperacyjnego postępowania kardiologicznego u pacjentów poddawanych zabiegom niekardiologicznym. Kardiol. Pol. 2010; 68. ; 3(supl. 2): S53–S108.
  2. Zardi EM, Zardi DM, Chin D, et al. Cirrhotic cardiomyopathy in the pre- and post-liver transplantation phase. J Cardiol. 2016; 67(2): 125–130.
  3. Zambruni A, Di Micoli A, Lubisco A, et al. QT interval correction in patients with cirrhosis. J Cardiovasc Electrophysiol. 2007; 18(1): 77–82.
  4. Gassanov N, Caglayan E, Semmo N, et al. Cirrhotic cardiomyopathy: a cardiologist's perspective. World J Gastroenterol. 2014; 20(42): 15492–15498.
  5. Sampaio F, Pimenta J, Bettencourt N, et al. Left atrial function is impaired in cirrhosis: a speckle tracking echocardiographic study. Hepatol Int. 2014; 8(1): 146–153.
  6. Naqvi IH, Mahmood K, Naeem M, et al. The heart matters when the liver shatters! Cirrhotic cardiomyopathy: frequency, comparison, and correlation with severity of disease. Prz Gastroenterol. 2016; 11(4): 247–256.
  7. Harinstein ME, Flaherty JD, Ansari AH, et al. Predictive value of dobutamine stress echocardiography for coronary artery disease detection in liver transplant candidates. Am J Transplant. 2008; 8(7): 1523–1528.
  8. Møller S, Hove JD, Dixen U, et al. New insights into cirrhotic cardiomyopathy. Int J Cardiol. 2013; 167(4): 1101–1108.
  9. Wong F, Villamil A, Merli M, et al. Prevalence of diastolic dysfunction in cirrhosis and its clinical significance. Hepatology. 2011; 54: 475A.
  10. Møller S, Wiese S, Halgreen H, et al. Diastolic dysfunction in cirrhosis. Heart Fail Rev. 2016; 21(5): 599–610.
  11. Kazankov K, Holland-Fischer P, Andersen NH, et al. Resting myocardial dysfunction in cirrhosis quantified by tissue Doppler imaging. Liver Int. 2011; 31(4): 534–540.
  12. Cartin-Ceba R, Krowka MJ. Portopulmonary hypertension. Clin Liver Dis. 2014; 18(2): 421–438.
  13. Pateron D, Beyne P, Laperche T, et al. Elevated circulating cardiac troponin I in patients with cirrhosis. Hepatology. 1999; 29(3): 640–643.
  14. Henriksen JH, Gøtze JP, Fuglsang S, et al. Increased circulating pro-brain natriuretic peptide (proBNP) and brain natriuretic peptide (BNP) in patients with cirrhosis: relation to cardiovascular dysfunction and severity of disease. Gut. 2003; 52(10): 1511–1517.
  15. Saner FH, Neumann T, Canbay A, et al. High brain-natriuretic peptide level predicts cirrhotic cardiomyopathy in liver transplant patients. Transpl Int. 2011; 24(5): 425–432.
  16. Licata A, Corrao S, Petta S, et al. NT pro BNP plasma level and atrial volume are linked to the severity of liver cirrhosis. PLoS One. 2013; 8(8): e68364.
  17. Epstein SK, Freeman RB, Khayat A, et al. Aerobic capacity is associated with 100-day outcome after hepatic transplantation. Liver Transpl. 2004; 10(3): 418–424.
  18. Dharancy S, Lemyze M, Boleslawski E, et al. Impact of impaired aerobic capacity on liver transplant candidates. Transplantation. 2008; 86(8): 1077–1083.
  19. Prentis JM, Manas DMD, Trenell MI, et al. Submaximal cardiopulmonary exercise testing predicts 90-day survival after liver transplantation. Liver Transpl. 2012; 18(2): 152–159.
  20. Galas M, Główczyńska R, Wasilewicz M, et al. Kardiomiopatia wątrobowa i zespół wątrobowo-płucny u pacjenta kwalifikowanego do transplantacji wątroby. Folia Cardiol. 2015; 10(3): 210–213.
  21. Cranney GB, Lotan CS, Dean L, et al. Left ventricular volume measurement using cardiac axis nuclear magnetic resonance imaging. Validation by calibrated ventricular angiography. Circulation. 1990; 82(1): 154–163.
  22. Lawton JS, Cupps BP, Knutsen AK, et al. Magnetic resonance imaging detects significant sex differences in human myocardial strain. Biomed Eng Online. 2011; 10: 76.
  23. Zardi EM, Zardi DM, Chin D, et al. Cirrhotic cardiomyopathy in the pre- and post-liver transplantation phase. J Cardiol. 2016; 67(2): 125–130.

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

 

Wydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl